Introduction: Fibrosis is the principal determinant of long-term outcomes in metabolic dysfunction–associated steatotic liver disease (MASLD). This large international Global-MASLD study evaluated clinical predictors of advanced fibrosis and assessed the prognostic value of noninvasive fibrosis tests (NITs) across nearly 18,000 biopsy-confirmed patients.
Introduction:
Fibrosis is the principal determinant of long-term outcomes in metabolic dysfunction–associated steatotic liver disease (MASLD). This large international Global-MASLD study evaluated clinical predictors of advanced fibrosis and assessed the prognostic value of noninvasive fibrosis tests (NITs) across nearly 18,000 biopsy-confirmed patients.
Why was this study needed?
Results:
Clinical Impact:
This landmark global study reinforces that fibrosis staging should remain the cornerstone of MASLD management. Simple noninvasive fibrosis tests provide powerful prognostic information and can reliably identify patients requiring specialist referral, HCC surveillance, and consideration for emerging antifibrotic therapies.
Bottom Line:
Fibrosis—not steatosis—is the key determinant of prognosis in MASLD. Type 2 diabetes, older age, and obesity are the major drivers of advanced fibrosis, while noninvasive fibrosis tests perform comparably to histology in predicting mortality and clinical outcomes, supporting their routine use in clinical practice.
Introduction: Obesity is increasingly recognized as a chronic, adiposity-based disease rather than a condition defined solely by body mass index (BMI). Recent guidelines from major international organizations have introduced new diagnostic frameworks that incorporate body...
Introduction: Noninvasive tests (NITs) have become central to the diagnosis and staging of metabolic dysfunction–associated steatotic liver disease (MASLD), reducing reliance on liver biopsy. However, most validation studies have been performed in selected populations, and...
Introduction: Identifying patients with at-risk metabolic dysfunction–associated steatohepatitis (MASH) is essential because they carry a substantially higher risk of cirrhosis, hepatocellular carcinoma, and liver-related mortality. Although liver biopsy remains the diagnostic standard, it is impractical...
Introduction: The transition from non alcoholic fatty liver disease (NAFLD) to the steatotic liver disease (SLD) nomenclature has redefined metabolic dysfunction–associated steatotic liver disease (MASLD) as the principal subtype. While studies in adults have shown...
Introduction: Accurate prediction of liver-related events (LREs) is essential for risk stratification and therapeutic decision-making in metabolic dysfunction–associated steatotic liver disease (MASLD). Although liver biopsy remains the reference standard for fibrosis assessment, vibration-controlled transient elastography...
Introduction: Obesity, insulin resistance, and metabolic dysfunction-associated steatotic liver disease (MASLD) are closely linked metabolic disorders with limited disease-modifying therapies. This study identifies CD59, traditionally known as a complement regulatory protein, as a previously unrecognized...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.